Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor–Positive Breast Cancer

Recent studies, including a meta-analysis of 88 trials, have shown higher than expected rates of recurrence and death in hormone receptor–positive breast cancer. These new findings suggest a need to re-evaluate the use of risk-reducing medication to avoid invasive breast cancer and breast cancer dea...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayasekera, Jinani, Zhao, Amy, Schechter, Clyde, Lowry, Kathryn, Yeh, Jennifer M., Schwartz, Marc D., O'Neill, Suzanne, Wernli, Karen J., Stout, Natasha, Mandelblatt, Jeanne, Kurian, Allison W., Isaacs, Claudine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901948/
https://www.ncbi.nlm.nih.gov/pubmed/36455167
http://dx.doi.org/10.1200/JCO.22.01342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901948/
https://www.ncbi.nlm.nih.gov/pubmed/36455167
http://dx.doi.org/10.1200/JCO.22.01342

Ejemplares similares